Latest News


ACC Liverpool Waterfront
08 August 2016

More than 50 world-class speakers on the latest scientific breakthroughs and new approaches in drug discovery research are to gather at one of the sector’s major conferences in Liverpool this autumn.

The ELRIG (European Laboratory Research and Innovation Group) Drug Discovery conference, the UK’s largest free to attend event of its kind, previously visited in 2009 and this year’s event takes place from the 13-14th October at ACC Liverpool.

It will bring together more than 1000 industry leaders from across the pharma, biotech, academia and vendor communities to discuss future opportunities for novel therapeutic discovery.

University of Liverpool’s Professor Sir Munir Pirmohamed, one of the country’s leading clinical experts, will be one of the main speakers at the flagship event, speaking on drug safety in drug development.

Dr Peter Simpson, director of the N8 Research Partnership, which is partnering with ELRIG, and who co-chaired last year’s Drug Discovery conference, said: “I’m absolutely convinced that bringing the whole community of academia, SMEs and major companies together truly fosters innovation and collaboration.

“It is wonderful to be returning to Liverpool and ideal that this event is returning to the North, a region where Health Innovation is highlighted as a major economic capability. Great advancement will come from quality research insights, informal discussions, and networking, to the benefit the drug discovery and life science communities.”

The six main sessions will cover: Innovations In Chemistry; Oncology and Immunology; Innovations in Predictive and Translational Models; Assay Development, Screening and Emerging Technologies; Coming Closer to the Patient – Cells and Genes in Therapy and Diagnostics; and Target Identification and Validation.

The conference will also explore innovative technologies and approaches that can be used to overcome drug development challenges.

Steve Rees, Chair of ELRIG and VP of Screening Sciences and Sample Management at AstraZeneca, said: “Typically attracting 1200 attendees, the Drug Discovery meeting provides a unique opportunity for scientists from academia, biotech, pharma and the vendor community to hear world leading speakers describe advances in target identification and preclinical drug discovery. 

“We are delighted to bring our tenth anniversary meeting to Liverpool and look forward to welcoming scientists from the N8 Universities to the meeting.”

There are still free delegate places remaining and during the mid-morning and lunchtime break there will be the chance to view relevant exhibits, vendors and poster displays.